View Older Stories View More Recent Stories

Aug 12, 2025 05:33AM KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasiv
Jul 24, 2025 05:00PM MilliporeSigma and Washington University in St. Louis Sign MoU to Advance Scientific Collaboration
Jul 22, 2025 11:53AM Merck Announces Fourth-Quarter 2025 Dividend
Jul 15, 2025 08:00AM MilliporeSigma Launches AAW™ Workstation to Advance Lab Automation
Jul 14, 2025 09:32AM Merck launches phase 3 trials for monthly HIV prevention pill
Jul 14, 2025 09:31AM Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill
Jul 10, 2025 04:45PM FDA approves Merck's BRAVECTO QUANTUM for year-long flea and tick protection
Jul 10, 2025 04:45PM FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health
Jul 10, 2025 06:45AM FDA accepts Merck's application for HIV two-drug regimen
Jul 10, 2025 06:45AM U.S. FDA Accepts New Drug Application for Merck’s Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection
Jul 9, 2025 06:30AM Merck to acquire Verona Pharma for $10 billion to add COPD treatment
Jul 9, 2025 06:30AM Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade
Jul 8, 2025 06:46AM Merck to present HIV research data at IAS 2025 conference
Jul 8, 2025 06:45AM Merck to Present New Data Highlighting Research Advancements Across its HIV Prevention and Treatment Pipeline at IAS 2025
Jul 2, 2025 06:45AM Merck (MRK) Granted FDA Priority Review for WINREVAIR to Update Label Based on Results From ZENITH Trial
Jul 2, 2025 06:45AM FDA Grants Priority Review for WINREVAIR™ (sotatercept-csrk) to Update Label Based on Results From ZENITH Trial
Jul 1, 2025 06:45AM Merck to Hold Second-Quarter 2025 Sales and Earnings Conference Call July 29
Jun 26, 2025 01:39PM Merck (MRK) Reports ACIP Recommended Use of ENFLONSIA for Prevention of RSV Lower Respiratory Tract Disease in Infants Younger than 8 Months
Jun 26, 2025 01:39PM ACIP Recommends Use of Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born During
Jun 24, 2025 06:45AM Merck to Hold Investor Event to Highlight Advancing Research Pipeline for HIV Treatment and Prevention
Jun 23, 2025 06:45AM Merck (MRK) Announces Phase 3 HYPERION Study of WINREVAIR Met Primary Endpoint
Jun 23, 2025 06:45AM Merck Announces Phase 3 HYPERION Study of WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Recently Diagnosed Adults with Pulmonary Arterial Hypertension (PAH)
Jun 18, 2025 08:00AM MilliporeSigma Announces Neoclease as Winner of 2025 North American Advance Biotech Grant
Jun 18, 2025 07:00AM IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer
Jun 13, 2025 06:46AM Merck (MRK) Announces FDA Approval of KEYTRUDA for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment
Jun 13, 2025 06:45AM FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiother
Jun 12, 2025 04:45PM Merck (MRK) Animal Health Receives EU CVMP Positive Opinion for NUMELVI Tablets for Dogs
Jun 12, 2025 04:45PM Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs
Jun 12, 2025 06:46AM Merck (MRK) Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate
Jun 12, 2025 06:45AM Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate
Jun 9, 2025 03:11PM U.S. FDA Approves Merck’s (MRK) ENFLONSIA for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season
Jun 9, 2025 03:11PM U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Seaso
Jun 9, 2025 06:45AM Merck (MRK) Reports Positive Topline Results From the First Two Phase 3 CORALreef Trials
Jun 9, 2025 06:45AM Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia
Jun 4, 2025 06:45AM Merck to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
May 31, 2025 08:00AM KEYTRUDA® (pembrolizumab) Plus Trodelvy® (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Neg
May 30, 2025 08:05AM Merck (MRK) Announces MK-1084 Shows Antitumor Activity in Phase 1 Trial of Patients With Advanced Colorectal Cancer and Non-Small Cell Lung Cancer Whose Tumors Harbor KRAS G12C Mutations
May 30, 2025 08:05AM Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor, Shows Antitumor Activity in Phase 1 Trial of Patients With Advanced Colorectal Cancer and Non-Small Cell Lung Cancer Whose Tumors Harbo
May 30, 2025 08:01AM Merck's (MRK) Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate
May 30, 2025 08:00AM Merck’s Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients With Relapsed/Refractory DLBC
May 29, 2025 07:00AM Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn
May 27, 2025 01:24PM Merck Announces Third-Quarter 2025 Dividend
May 22, 2025 06:45AM Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference
May 19, 2025 07:01AM IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
May 19, 2025 07:00AM IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
May 16, 2025 06:45AM Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society’s (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial H
May 15, 2025 06:45AM Merck (MRK) Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival
May 15, 2025 06:45AM Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All C
May 14, 2025 05:30PM Merck (MRK) announces FDA approval of WELIREG
May 14, 2025 05:15PM FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Adults and Pediatric Patients 12 Years and Older With Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma
View More Recent Stories View Older Stories